Background
Results
The expression level of TLR9 was higher in colonic LP CD5 
Conclusion
A persistent altered mucosal B cell population caused by chronic gut inflammation may be involved in the pathogenesis of inflammatory bowel diseases.
Introduction
B cells are generally well known as antibody-producing cells that play a key role in adaptive immune response under physiological and pathological conditions. [1] However, their role in innate immune-related disorders has not been fully elucidated. CD5 + B cells are a unique subset of B cells localized mainly in peritoneal and pleural cavities, and appear to be involved in an innate immune system that is able to sense pathogen-associated molecular patterns (PAMPs) and initiate immune response by secretion of natural polyreactive antibodies, [2] thus limiting bacterial spread before induction of an adaptive immune reaction. It has been shown that CD5 + B cells have protective roles against influenza and schistosomal infection through natural
IgM antibodies or Fas ligands. [3, 4] In contrast, CD5 -B cells, predominately localized in the spleen and lymph nodes, participate in adaptive immunity by producing antigen-specific antibodies that interact with helper T cells. Previous studies have reported conflicting results regarding the functions of CD5 + B cells in autoimmune diseases. Autoantibodies produced by those cells have been identified as potentially contributing to the development of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren's syndrome, [5] [6] [7] and depletion of this subset decreases pathogenic autoantibodies, leading to a reduction of disease activity. On the other hand, CD5 + B cells are associated with regulation of experimental autoimmune encephalitis (EAE) through secretion of anti-inflammatory cytokines or decreased expression of the chemokine receptor CXCR5. [8, 9] Therefore, CD5
+ B cells may function as a double-edged sword in autoimmune and infectious diseases, though the discrepant findings thus far presented might be related to the timing of intervention with this B cell subset.
Of note, multiple studies have demonstrated that CD5 + B cells are protective in cases of intestinal inflammation by generating natural antibodies against microbial flora [10] and producing IL-10. [11, 12] Intestinal CD5 + B cells are also the main source of IgA secretion, [13, 14] which can continuously protect the body from threat of infection by pathological bacteria and maintain a normal flora composition. Therefore, intestinal CD5 + B cells appear to have important roles in regulatory immunity in cases of mucosal inflammation and homeostasis.
In the present study, we investigated the involvement of colonic CD5 + B cells and compared them with CD5 -B cells using model mice with acute or chronic colitis. Our results demonstrate that chronic intestinal inflammation decreases the frequency of CD5 + B cells and leads to a sustained CD5 -B cell-dominant condition, which may be involved in the pathogenesis of refractory inflammatory bowel diseases (IBD).
Materials and Methods

Reagents
The following reagents were employed. For flow cytometry: FITC-, PE-, and PE-Cy5-conjugated anti-mouse CD5 (53-7.3), B220 (RA3-6B2), CD11b (M1/70), IgM (R6-60.2) (BD Biosciences-Pharmingen, San Jose, CA), TLR4/MD2 (UT41), and TLR9 (Imgenex Biotech, Orissa, India). For B cell isolation: FcR blocking reagent, anti-CD5 microbeads (catalog # 130-049-301) and a B cell isolation kit, mouse (catalog # 130-090-862) (Miltenyi, San Diego, CA). For cell cultures: ultra-pure E.coli LPS (0111:B4 strain) (Invivogen, San Diego, CA). Unmethylated CpG-DNA (5'-TGACTGTGAACGTTCGAGATGA-3') was synthesized by Hokkaido System Science Co., Ltd. (Hokkaido, Japan).
Animals and experimental colitis
Seven-week-old male specific pathogen-free BALB/c mice were obtained from Nihon Clea (Tokyo, Japan). After an initial adaptation period of 1 week, a dextran sulfate sodium (DSS) (5 kDa; Wako Pure Chemical Industries, Osaka, Japan) solution (2.5% w/v) was administered to the experimental group as drinking water for 7 days, with the solution changed every other day, to induce colitis. Mouse conditions were carefully monitored three times a week after DSS administration until termination of the study. The control group was given normal water lacking DSS. In parallel, chronic colitis was induced in some mice by repeating administrations of DSS solution. Each cycle consisted of a 7-day exposure to DSS, followed by a 14-day period without DSS, which continued for up to 7 cycles. At 14 days after the DSS period following completion of 1, 3, 5, or 7 cycles, mice were euthanized under diethyl ether anesthesia by quick cervical distortion to minimize animal suffering and evaluated. Two mice in the chronic colitis model group were excluded from analysis, because of development of colorectal tumors (after 5 and 7 cycles, respectively). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institute for Animal Experimentation of Shimane University (Protocol Number: IZ21-108).
Cell isolation
Mononuclear cells were isolated from several of the mouse organs, using a method previously described. [15] Peritoneal cavity (PerC) cells were collected after intraperitoneal injection of Ca
2+
-and Mg 2+ -free Hanks' balanced salt solution (HBSS; Gibco-Invitrogen) with 2% fetal bovine serum (FBS; ICN Biomedicals, Aurora, OH, USA). Mesenteric lymph nodes (MLN) were crushed through 70-μm filters into phosphate-buffered saline (PBS) with 2% FBS. Spleens were mechanically dissociated and red blood cells were lysed in ammonium phosphate/chloride lysis buffer. For isolating colon lamina propria mononuclear cells (LPMC), we used only the distal part of the colon, which is the area susceptible to DSS-induced colitis. Colons were opened longitudinally and washed extensively with cold PBS, then cut into 5-mm pieces. Obtained tissues were incubated in 1 mM DTT (Sigma-Aldrich, St. Louis, Missouri, USA) for 15 minutes at room temperature and then 1 mM EDTA 3 times at 37°C for 20 minutes each, followed by HBSS with 1 mg/ml of collagenase type 3 (Worthington Biochemical Corporation, Lakewood, New Jersey, USA), 0.1 mg/ml of DNase I (Worthington Biochemical Corporation), 2% FBS, and 1% penicillin-streptomycin (Gibco-Invitrogen) for 60 minutes at 37°C. Cell suspensions were filtered through a nylon mesh and centrifuged, then LPMC were purified using a 44-70% discontinuous Percoll gradient (GE Healthcare, Buckinghamshire, UK). After centrifugation at 800 x g for 20 minutes at 22°C, cells were collected from the interface, and washed and re-suspended in PBS with 2% FBS. Cell viability was greater than 90%, as determined by eosin Y exclusion. ) were separately cultured at 200 μl/well in 96-well plates for 72 hours at 37°C with 5% CO 2 . The culture medium was RPMI 1640 (Gibco-Invitrogen) containing 10% FBS and 1% penicillin-streptomycin-amphotericin B (Gibco-Invitrogen), with or without LPS (100 ng/ml) or CpG-DNA (1 nM). Following the cell cultures, the supernatants were collected for measurements of IL-10 by ELISA.
Flow cytometry
Three-color flow cytometric analyses were performed. Cells were stained with appropriate antibodies on ice, as previously described, for 20 minutes to detect cell surface markers. In some experiments, cells were further fixed and permeabilized with Intraprep (Beckman Coulter, Fullerton, CA, USA) and stained intracellularly with anti-TLR9. After washing, the cells were immediately subjected to flow cytometry (EPICS XL, Beckman Coulter, Tokyo, Japan), and analyzed using EXPO32 TM software. Isotype-matched antibodies were used to determine the level of non-specific staining.
Measurement of IL-10 level
The level of IL-10 in supernatant was measured using a mouse IL-10 Quantikine ELISA Kit (R&D systems, Minneapolis, MN), according to the manufacturer's instructions. Briefly, appropriate sample amounts were transferred into the wells of anti-mouse IL-10-coated microtiter strips and a secondary biotinylated monoclonal antibody was added. After washing, the samples were incubated with streptavidin-peroxidase. A substrate solution was then added to produce color directly proportional to the concentration of IL-10 present in the sample. Quantitative results were obtained from a standard curve produced from the experimental findings. IL-10 levels in the TLR-stimulated cultures were normalized by that in the cultures without TLR ligands.
Statistical analysis
All data are expressed as the mean ± standard deviation (SD). Values were analyzed using Student's t test and Spearman's rank correlation with Stat-View 4.0 software (Abacus Concepts, Inc., USA). For comparisons of multiple values, ANOVA was used. P values less than 0.05 were considered to be significant. PerC CD5 + B cells (Fig 2) . Taken together, the population and phenotype of CD5 + B cells in the colonic LP were different from those of PerC CD5 + B cells
Results
Distribution and characteristics of CD5 + and CD5 -B cells in normal mice
Intestinal CD5 + B cells produce a greater amount of IL-10 in response to TLR stimulation than CD5 -B cells
Since splenic and PerC CD5 + B cells are protective against colitis, [10, 12] we examined the relative production levels of the anti-inflammatory cytokine IL-10 in TLR-stimulated colonic LP CD5 + and CD5 -B cells in vitro (Fig 3A) . Colonic LP CD5 + B cells produced greater amounts of IL-10 following stimulation with TLR ligands, especially TLR9, as compared with the LP CD5 -B cells (Fig 3B) , which might have been due to the higher expression level of TLR9 in intestinal CD5 + B cells (Fig 2) . These results suggest that TLR9-medeated IL-10 production may be one of the regulatory mechanisms of intestinal CD5 + B cells in regard to gut inflammation and homeostasis.
Acute intestinal inflammation transiently decreases the frequency of mucosal CD5 + B cells
Although B cells attenuate colitis through multiple mechanisms, [12, 16, 17] little is known regarding whether intestinal inflammation itself influences the involvement of B cell subsets. 
Intestinal CD5 + B Cells in Colonic Inflammation
Therefore, we investigated the frequency of the colonic LP B cell subpopulation in response to intestinal inflammation. Using an acute model of DSS-induced colitis, histological inflammation characterized by massive cellular infiltration with edema was shown on day 8, and then the severity of colitis decreased and nearly recovered morphologically by day 21 (Fig 4A) . Interestingly, the population of colon LP CD5 + B cells among total B cells (30.2±2.5%) was significantly decreased on day 8 (23.5±3.5%) and minimal on day 14 (10.8±1.9%, 35.7% decrease as compared with noninflamed colon). Thereafter, the population began to restore and finally recovered up to 25.2 ±3.5% (83.4% decrease as compared with control) on day 21 (Fig 4B and 4C) . The ratio of CD5 + B cells among PerC was not significantly affected by mucosal inflammation (S1A Fig) Although acute mucosal inflammation transiently alters the distribution of colonic LP B cells, human IBD is associated with chronic intestinal inflammation with repeating relapse and remission. Therefore, we next examined the intestinal B cell subsets in a chronic mucosal injury model. Although the 14-day recovery period after ending DSS treatment (day 21) was nearly enough to recover histological inflammation and alternation of B cell subsets in acute colitis, repeated DSS treatments resulted in development of chronic intestinal inflammation characterized by thickened mucosal and submucosal layers, moderate mononuclear-cell filtration, and huge lymphoid aggregations on day 21 during the third, fifth, and seventh cycles (Fig 5A) . Notably, chronic intestinal inflammation significantly decreased the frequency of CD5 + B cells over time, resulting in a sustained CD5 -B cell-dominant condition (Fig 5B and 5C anti-inflammatory property, [16, 19] and IL-10-producing regulatory B cells require IL-27 signaling-mediated IL-10-secretion by T cells to confer protection against T cell-mediated colitis.
[16] Therefore, classification of the mucosal B cell population and evaluation of its functional aspects in regard to the interaction with other types of immune cells are important to understand the functions of the mucosal immune system in IBD. CD5 localized on the surface of B cells has been reported to be an important cell surface marker able to distinguish regulatory B cells in infectious and autoimmune diseases. [2, 3, 20, 21] However, this B cell subset also appears to be involved in the pathogenesis of IBD. [12, 18] Interestingly, the frequency of peripheral and mucosal CD5 + B cells was found to be lower in human UC patients as compared to healthy volunteers, [22, 23] and corticosteroid therapy further decreased the percentage of CD5 + B cells in UC patients. [22] In the present study, we found that colonic LP CD5 + B cells were primarily composed of B220 hi CD5 lo , while PerC CD5 + B cells possessed mainly the B220 mid CD5 mid (B-1) phenotype, which was previously reported to regulate chronic colitis by generating natural antibodies in response to microbial seems to play a protective role in patients with IBD [24, 25] and TLR9 mRNA levels were reported to be significantly higher in inflamed mucosa from UC patients as compared with normal subjects. [26] Moreover, the expression level of TLR9 in peripheral B cells from IBD patients was found to be greatly increased. [27] Together, these findings suggest that IL-10 secretion via TLR9 signaling may be a potential mechanism used by intestinal CD5 Supporting Information 
